Ruiz van Haperen VW - Search Results

1

Interaction between cisplatin and gemcitabine in vitro and in vivo.

Peters GJ, Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Braakhuis BJ. Peters GJ, et al. Among authors: ruiz van haperen vw. Semin Oncol. 1995 Aug;22(4 Suppl 11):72-9. Semin Oncol. 1995. PMID: 7481849

2

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.

Bergman AM, Eijk PP, Ruiz van Haperen VW, Smid K, Veerman G, Hubeek I, van den Ijssel P, Ylstra B, Peters GJ. Bergman AM, et al. Among authors: ruiz van haperen vw. Cancer Res. 2005 Oct 15;65(20):9510-6. doi: 10.1158/0008-5472.CAN-05-0989. Cancer Res. 2005. PMID: 16230416

3

Concentration and time dependent growth inhibition and metabolism in vitro by 2',2'-difluoro-deoxycytidine (gemcitabine).

Ruiz van Haperen VW, Veerman G, Noordhuis P, Vermorken JB, Peters GJ. Ruiz van Haperen VW, et al. Adv Exp Med Biol. 1991;309A:57-60. doi: 10.1007/978-1-4899-2638-8_12. Adv Exp Med Biol. 1991. PMID: 1789270 No abstract available.

4

Induction of resistance to 2',2'-difluorodeoxycytidine in the human ovarian cancer cell line A2780.

Ruiz van Haperen VW, Veerman G, Eriksson S, Stegmann AP, Peters GJ. Ruiz van Haperen VW, et al. Semin Oncol. 1995 Aug;22(4 Suppl 11):35-41. Semin Oncol. 1995. PMID: 7481843

5

Schedule-dependent antitumor effect of gemcitabine in in vivo model system.

Braakhuis BJ, Ruiz van Haperen VW, Boven E, Veerman G, Peters GJ. Braakhuis BJ, et al. Among authors: ruiz van haperen vw. Semin Oncol. 1995 Aug;22(4 Suppl 11):42-6. Semin Oncol. 1995. PMID: 7481844

6

Synergistic interaction between cisplatin and gemcitabine in ovarian and colon cancer cell lines.

Bergman AM, Ruiz van Haperen VW, Veerman G, Kuiper CM, Peters GJ. Bergman AM, et al. Among authors: ruiz van haperen vw. Adv Exp Med Biol. 1994;370:139-43. doi: 10.1007/978-1-4615-2584-4_32. Adv Exp Med Biol. 1994. PMID: 7660877 No abstract available.

7

Schedule dependence of sensitivity to 2',2'-difluorodeoxycytidine (Gemcitabine) in relation to accumulation and retention of its triphosphate in solid tumour cell lines and solid tumours.

Ruiz van Haperen VW, Veerman G, Boven E, Noordhuis P, Vermorken JB, Peters GJ. Ruiz van Haperen VW, et al. Biochem Pharmacol. 1994 Oct 7;48(7):1327-39. doi: 10.1016/0006-2952(94)90554-1. Biochem Pharmacol. 1994. PMID: 7945430

8

New targets for pyrimidine antimetabolites for the treatment of solid tumours. 2: Deoxycytidine kinase.

Ruiz van Haperen VW, Peters GJ. Ruiz van Haperen VW, et al. Pharm World Sci. 1994 Apr 15;16(2):104-12. doi: 10.1007/BF01880661. Pharm World Sci. 1994. PMID: 7980770 Review.

9

Development and molecular characterization of a 2',2'-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780.

Ruiz van Haperen VW, Veerman G, Eriksson S, Boven E, Stegmann AP, Hermsen M, Vermorken JB, Pinedo HM, Peters GJ. Ruiz van Haperen VW, et al. Cancer Res. 1994 Aug 1;54(15):4138-43. Cancer Res. 1994. PMID: 8033147

10

2',2'-Difluoro-deoxycytidine (gemcitabine) incorporation into RNA and DNA of tumour cell lines.

Ruiz van Haperen VW, Veerman G, Vermorken JB, Peters GJ. Ruiz van Haperen VW, et al. Biochem Pharmacol. 1993 Aug 17;46(4):762-6. doi: 10.1016/0006-2952(93)90566-f. Biochem Pharmacol. 1993. PMID: 8363650

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

25 results

Search Page

Filters